Mast cell activation syndrome, explained

Imagine a smoke alarm so sensitive it goes off when you make toast, run a hot shower, or feel stressed — and when it fires, it doesn't just beep in one room but sets off alarms all over the house at once. That is a useful way to picture mast cell activation syndrome, or MCAS: a single type of immune cell releasing its chemical payload too readily, producing symptoms across several body systems at the same time.

MCAS is a genuinely tricky diagnosis, and it deserves an honest treatment. It is real, it can be disabling, and it is under-recognised in some patients. It is also over-diagnosed in others, because its symptoms overlap with a long list of common conditions. The way through both problems is the same: understand what mast cells actually do, recognise the pattern, and hold the diagnosis to objective evidence rather than symptoms alone.

One cell, many systems: an overactive mast cell releases mediators that produce symptoms across skin, gut, heart, airways and nervous system at once.

Meet the mast cell

Mast cells are immune cells that live in your tissues — concentrated exactly where your body meets the outside world: the skin, the lining of the gut and airways, and around blood vessels and nerves. They are first responders, packed with granules full of pre-made chemical mediators. When triggered, they release these mediators in seconds.

The classic trigger is an allergy: an allergen cross-links IgE antibodies on the mast cell surface and it degranulates. But — and this matters for MCAS — mast cells also fire through many non-allergic routes: certain medications, physical stimuli (heat, cold, pressure, exercise), infections, hormonal shifts, and nerve signals. That is why so many people with MCAS react to things that aren't true allergies.

Mast cells fire through allergic (IgE) and many non-allergic triggers, releasing mediators that each explain part of the symptom picture. Tryptase is the one we can measure.

The trouble isn't that mast cells activate — they're supposed to. It's that in MCAS they activate too easily, too often, and out of proportion to the threat.

What it feels like: the symptoms

Because mast cells sit in every tissue, an activation episode tends to hit several systems at once. The hallmark of MCAS is exactly that: episodic, multisystem symptoms, often set off by an identifiable trigger, that come and go rather than staying constant.

The most severe end of this spectrum is anaphylaxis — a rapid, dangerous reaction with a drop in blood pressure. In fact, one useful clinical clue is that genuine MCAS usually involves these severe, systemic episodes; a long list of chronic, low-grade symptoms without any acute reactions makes it much less likely.

MCAS is defined partly by its pattern — recurrent episodes hitting two or more systems together, often after a trigger. Any single symptom is non-specific; the clustering is the clue.

Not one disease: the three types

"MCAS" is really an umbrella for a few different situations, and telling them apart changes the workup:

Primary (clonal) MCAS — the mast cells themselves are abnormal, carrying a mutation (most often KIT D816V). This sits on the spectrum of mastocytosis, and it's why a persistently high baseline tryptase prompts a haematology referral and sometimes a bone-marrow biopsy.

Secondary MCAS — the mast cells are normal but are being driven by an identifiable cause, most commonly a true IgE allergy, but also autoimmune or inflammatory conditions.

Idiopathic MCAS — the criteria are met but no clonal disease or trigger is found. This is a diagnosis reached only after the others are excluded.

A common curveball — hereditary alpha-tryptasemia: around 3–5% of people carry extra copies of the tryptase gene (TPSAB1), which raises their baseline tryptase without any disease. It's a frequent reason for a "high tryptase" result and can amplify symptoms — but on its own it is a genetic trait, not MCAS. Interpreting tryptase without accounting for it leads to mistakes in both directions.

Getting the diagnosis right

This is where discipline matters most. The international consensus requires all three of the following criteria — not just typical symptoms: recurrent episodic symptoms involving two or more organ systems; objective evidence of mast cell activation; and a response to mast-cell-targeted therapy.

All three criteria must be met. The 20% + 2 rule is the objective anchor: an acute tryptase drawn 1–4 hours into an episode must exceed baseline by at least 20% plus 2 ng/mL.

Why the insistence on objective evidence? Because nearly every individual symptom of MCAS is also caused by far more common conditions. Holding to the criteria is what protects patients from both a missed diagnosis and a wrong one — and a wrong MCAS label can send someone down years of unnecessary restriction and treatment while the real problem goes unaddressed.

How it's treated

Treatment is a ladder: start simple, add layers only as needed, and — crucially — introduce one thing at a time. MCAS bodies are sensitive, so the guiding principle is start low, go slow. The aim isn't to silence mast cells completely, but to turn the volume down enough to restore normal life.

Most people are controlled on the lower rungs. Short steroid courses settle severe flares; epinephrine is the rescue for anaphylaxis.

A note on expectations: finding the right combination takes patience, and it's normal for it to involve some trial and error over weeks. Cromolyn in particular can briefly worsen symptoms before it helps. Good care means changing one variable at a time so you can actually tell what's working.

Where this meets the gut

The gut is one of the richest sites of mast cells in the body, so digestive symptoms — cramping, diarrhoea, nausea, reflux, food reactions — are among the most common and most debilitating features of MCAS. This is also where the overlap with other conditions is greatest: irritable bowel syndrome, food intolerances, SIBO and mast-cell involvement can look strikingly similar, and they can coexist.

That overlap cuts both ways. Some people with a firm IBS label actually have a mast-cell-driven component that responds to stabilisers like cromolyn; others carry an MCAS label for gut symptoms that a proper gastroenterological workup explains and resolves. Sorting this out — rather than assuming — is exactly the kind of problem worth investigating carefully.

The bottom line

• MCAS is one cell misbehaving in many places. Overactive mast cells release mediators that hit skin, gut, heart, airways and nervous system together.

• The pattern is the clue. Episodic, multisystem, often triggered symptoms — frequently including severe, anaphylaxis-like reactions.

• Diagnosis needs objective proof. All three criteria, anchored by the 20% + 2 tryptase rule; symptoms alone are not enough.

• Context matters. Rule out mastocytosis and account for hereditary alpha-tryptasemia and common mimics before settling on MCAS.

• Most people improve. A stepwise ladder — antihistamines, stabilisers and beyond — controls symptoms in the majority, with epinephrine on hand for anaphylaxis.

A note from the clinic

Because so much of MCAS plays out in the gut — and overlaps with IBS, food reactions and SIBO — a careful gastroenterological assessment is often part of getting the picture right, alongside allergy/immunology for the systemic and diagnostic side. The goal at Shore Gastroenterology is to neither miss a genuine mast-cell problem nor apply the label where the evidence isn't there. If troubling gut symptoms and multisystem reactions are affecting you, they're worth working up properly.

Selected reading

• Valent P, Akin C, Arock M, et al. Consensus criteria and the 20% + 2 tryptase formula for mast cell activation syndrome, 2019–2024.

• AAAAI Mast Cell Disorders Work Group and international mastocytosis working group reports on MCAS diagnosis.

• Reviews on hereditary alpha-tryptasemia (TPSAB1) and interpretation of elevated baseline tryptase.

• Contemporary reviews on the stepwise pharmacological management of mast cell activation disorders.

This article is general educational information about mast cell activation syndrome. It is not individual medical advice and is not a substitute for assessment by a qualified clinician. MCAS diagnosis and treatment should be undertaken with appropriate specialist input. If you have symptoms or health concerns — particularly severe allergic-type reactions — please seek personalised medical advice, and call emergency services for anaphylaxis.